Background：Glofitamab RG6026 is a novel T-cell-engaging, bispecific antibody that binds bivalently to CD20 on B cells, and monovalently to CD3 on T cells. In study NP30179 NCT03075696, an ongoing Phase I/II dose-escalation and expansion study, glofitamab fixed-dosing 0.6-25mg with obinutuzumab pre-treatment Gpt achieved high, durable CRs with manageable safety in pts with heavily pre-treated R/R NHL Dickinson et al. EHA 2020. Step-up dosing SUD of glofitamab, in addition to Gpt, allowed dose-escalation up to the highest planned dose of 30mg to maximize efficacy, while mitigating cytokine release syndrome CRS; [Hutchings et al. J Clin Oncol 2021]. We present updated duration of response DoR data from the glofitamab monotherapy fixed-dosing and SUD cohorts of study NP30179 in pts with R/R NHL.
